M. Ratner

发表

Profile: Daphne Zohar

M. Ratner, 2006, Nature Biotechnology.

FDA to oversee reporting of clinical trials

M. Ratner, 2012, Nature Biotechnology.

FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label

M. Ratner, 2017, Nature Biotechnology.

Gilead bets big on Nimbus' fatty liver disease drug

M. Ratner, 2016, Nature Biotechnology.

Neuroimaging heats up

M. Ratner, 2005, Nature Reviews Drug Discovery.

Pharma swept up in biogenerics gold rush

M. Ratner, 2009, Nature Biotechnology.

Pfizer stakes a claim in plant cell–made biopharmaceuticals

M. Ratner, 2010, Nature Biotechnology.

Faster approval for breakthrough devices

M. Ratner, 2014, Nature Biotechnology.

The Year in Review

M. Ratner, 1990, Bio/Technology.

Syrrx acquisition signals maturation of structure-based discovery

M. Ratner, 2005, Nature Biotechnology.

Off-label or off-limits?

T. Gura, M. Ratner, 2008, Nature Biotechnology.

Erythropoietins locked into risk management program

M. Ratner, 2010, Nature Biotechnology.

Genentech discloses safety concerns over Avastin

M. Ratner, 2004, Nature Biotechnology.

Landmark approvals in idiopathic pulmonary fibrosis

M. Ratner, 2014, Nature Biotechnology.

Genentech's PD-L1 agent approved for bladder cancer

M. Ratner, 2016, Nature Biotechnology.

First multi-gene NGS diagnostic kit approved

M. Ratner, 2017, Nature Biotechnology.

Genentech's glyco-engineered antibody to succeed Rituxan.

M. Ratner, 2014, Nature biotechnology.

IL-17–targeting biologics aim to become standard of care in psoriasis

M. Ratner, 2015, Nature Biotechnology.

A New Era for Genentech, And So It Goes

M. Ratner, 1990, Bio/Technology.

Biogen's early Alzheimer's data raise hopes, some eyebrows

M. Ratner, 2015, Nature Biotechnology.

Roche plans for more convenient-to-use Herceptin and Rituxan

M. Ratner, 2010, Nature Biotechnology.

Microbial cocktails raise bar for C. diff. treatments

M. Ratner, 2020, Nature Biotechnology.

Microbial cocktails join fecal transplants in IBD treatment trials

M. Ratner, 2015, Nature Biotechnology.

Alexion pays big for Synageva's rare disease drug candidate

M. Ratner, 2015, Nature Biotechnology.

Human Genome Sciences trial data wow lupus community

M. Ratner, 2009, Nature Biotechnology.

AN APPRECIATION OF THE STOICHIOMETRIC NUMBER METHOD FROM THE VIEWPOINT OF QUANTUM STATISTICAL MECHANICS

M. Ratner, M. Ratner, 1973, Annals of the New York Academy of Sciences.

FDA panel votes to pull Avastin in breast cancer, again

M. Ratner, 2011, Nature Biotechnology.

FDA pharmacogenomics guidance sends clear message to industry

Mark Ratner, M. Ratner, 2005, Nature reviews. Drug discovery.

China steps up US biotech intellectual property land grab

M. Ratner, 2008, Nature Biotechnology.

Despite the Best of Intentions

M. Ratner, 1991, Bio/Technology.

An Analysis of the Nutritional Adequacy of Mass-Marketed Vegan Recipes

M. Ratner, C. Keen, Mary G. Graham, 2023, Cureus.

Seres's pioneering microbiome drug fails mid-stage trial

M. Ratner, 2016, Nature Biotechnology.

Conference on Molecular Electronics: Science and Technology, Puerto Rico, 14-18 December 1997: Preface

A. Aviram, A. Aviram, M. Ratner, 1998 .

Setback for JAK2 inhibitors

M. Ratner, 2014, Nature Biotechnology.

Pfizer settles largest ever fraud suit for off-label promotion

M. Ratner, 2009, Nature Biotechnology.

Fecal transplantation poses dilemma for FDA

M. Ratner, 2014, Nature Biotechnology.

Next-generation AMD drugs to wed blockbusters

M. Ratner, 2014, Nature Biotechnology.

Genentech's glyco-engineered antibody to succeed Rituxan

M. Ratner, 2014, Nature Biotechnology.

FDA backs clinician-free AI imaging diagnostic tools

M. Ratner, 2018, Nature Biotechnology.

Protein Expression in Yeast

M. Ratner, 1989, Nature Biotechnology.

Genzyme resumes shipping as Sanofi-aventis hovers

M. Ratner, 2010, Nature Biotechnology.

Reality check for device-drug convergence

Mark Ratner, M. Ratner, 2007, Nature Biotechnology.

Survey and Opinions: Barriers to Field-Testing Genetically Modified Organisms

M. Ratner, 1990, Bio/Technology.

Pfizer reaches out to academia—again

M. Ratner, 2011, Nature Biotechnology.

Looking for solid ground along the Critical Path

M. Ratner, 2006, Nature Biotechnology.

Fearful of Avastin's fate, Genentech asks for unusual hearing

M. Ratner, 2011, Nature Medicine.

Odds still favor Novartis heart failure drug Serelaxin

M. Ratner, 2014, Nature Biotechnology.

The Year in Review

M. Ratner, 1990, Bio/Technology.

Big pharma upheavals cast shadow across biotech sector

Mark Ratner, M. Ratner, 2012, Nature Biotechnology.

Seres's pioneering microbiome drug fails mid-stage trial

M. Ratner, 2016, Nature Biotechnology.

Off-the-shelf CAR-T therapy induces remission in child with ALL

M. Ratner, 2016, Nature Biotechnology.

Complement inhibitors finally find orphan niches

M. Ratner, 2006, Nature Biotechnology.